PCR Stock Overview
PCC Rokita SA manufactures and distributes chemical products in Poland and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
PCC Rokita SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł131.20 |
| 52 Week High | zł135.80 |
| 52 Week Low | zł70.20 |
| Beta | 1.11 |
| 1 Month Change | 10.07% |
| 3 Month Change | 36.95% |
| 1 Year Change | 37.10% |
| 3 Year Change | 328.76% |
| 5 Year Change | 16.62% |
| Change since IPO | 295.66% |
Recent News & Updates
Recent updates
Is PCC Rokita (WSE:PCR) A Risky Investment?
Jan 18
PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23
Apr 16Why We Like The Returns At PCC Rokita (WSE:PCR)
Mar 19What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?
Jan 25We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)
Sep 01Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching
Jun 14Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?
May 18Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes
Apr 13Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem
Mar 23PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Mar 09Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?
Feb 19
What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?
Feb 04Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Jan 15Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?
Dec 30Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years
Dec 17PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Dec 03Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?
Nov 20Shareholder Returns
| PCR | PL Chemicals | PL Market | |
|---|---|---|---|
| 7D | 11.2% | 0.3% | -1.4% |
| 1Y | 37.1% | 2.6% | -13.5% |
Return vs Industry: PCR exceeded the Polish Chemicals industry which returned -0.7% over the past year.
Return vs Market: PCR exceeded the Polish Market which returned -14.2% over the past year.
Price Volatility
| PCR volatility | |
|---|---|
| PCR Average Weekly Movement | 4.7% |
| Chemicals Industry Average Movement | 4.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.8% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: PCR is not significantly more volatile than the rest of Polish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PCR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,791 | Wieslaw Klimkowski | https://www.pcc.rokita.pl |
PCC Rokita SA manufactures and distributes chemical products in Poland and internationally. The company offers chlorine and alkali; polyurethanes; specialty products; and surfactants products, as well as polyols, naphthalene, and phosphorus derivatives. It serves agrochemicals, adhesives, industrial cleaning and washing, detergents, paints and varnishes, tanning, glues, cosmetics and personal hygiene products, vehicle washing and care, chemical reagents, textiles, extraction and production, packaging, firefighting, construction, pulp and paper, refrigeration and household appliances, energy, pharmaceutical, furniture, metallurgical, fuel, food, mining, sport and recreation, chemical raw material and intermediates, lubricating and industrial fluids, fiber optic technologies, transport, printing inks, plastics, and water and waste water treatment industries.
PCC Rokita SA Fundamentals Summary
| PCR fundamental statistics | |
|---|---|
| Market Cap | zł2.60b |
| Earnings (TTM) | zł568.76m |
| Revenue (TTM) | zł2.82b |
4.6x
P/E Ratio0.9x
P/S RatioIs PCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCR income statement (TTM) | |
|---|---|
| Revenue | zł2.82b |
| Cost of Revenue | zł1.88b |
| Gross Profit | zł938.31m |
| Other Expenses | zł369.55m |
| Earnings | zł568.76m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
May 16, 2023
| Earnings per share (EPS) | 28.65 |
| Gross Margin | 33.27% |
| Net Profit Margin | 20.16% |
| Debt/Equity Ratio | 46.5% |
How did PCR perform over the long term?
See historical performance and comparison